Merck Sharp & Dohme (MSD) have developed a clinical protocol that identifies the inclusion criteria to support an Expanded Access program in Australia for raltegravir that is in line with the current TGA approved indication for this product.

The development of this program is in response to recent requests from physicians for compassionate supply of ISENTRESS based on a number of clear and significant clinical needs. MSD plans to make this Expanded Access program available in Australia in February 2010.

 

Further details on this program are available from Dr Jasmine Chua phone: 02 9795 9065 email: jasmine_chua@merck.com and Mrs Katherine Thatcher phone: 02 9795 9324 email: katherine_thatcher@merck.com.